Table 1.

Study Population Characteristics.

	Eligible study cohort n=37	Ineligible study cohort n=39	P value
Age, years ±SD	54 ± 11	53 ± 12(* missing data n=4)	ns
Male %	56.8	56.4	ns
Race %
- Caucasian	73.0	69.2	ns
- African American	21.6	18
- Other	5.4	12.8
Smokers % (A/F/N)	0 / 32.4 / 67.6	0 / 25.6 / 74.4	ns
Pre-MMF immunosuppressive therapy* %(n)	Prednisone 75.7 (28)	Prednisone 61.5 (24)	<0.05
	Methotrexate 70.3 (26)	Methotrexate 33.3 (13)
	No therapy 0.05 (2)	No therapy 23.1 (9)
	Hydroxychloroquine 0.05 (2)	Hydroxychloroquine 0.05 (2)
	Azathioprine 0.03 (1)	Leflunomide 0.03 (1)

Abbreviations: ns: not significant, SD: Standard deviation, A/F/N: Active/Former/Never. N/A: Not applicable, IS: Immunosuppressive, MMF: Mycophenolate Mofetil

^*most patients were on combination therapy